European Alliance of Associations for Rheumatology Annual Congress (EULAR 2025)
Barcelona, Spain 11 June 2025 - 14 June 2025
RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals
A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.
RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals
16 Jul 2025
Deucravacitinib delivers superior efficacy, safety in active PsA
Deucravacitinib exhibits superiority over placebo in terms of overall disease activity measures, musculoskeletal and dermatologic manifestations, and quality of life in adults with active psoriatic arthritis (PsA) who are naïve to biologic disease-modifying antirheumatic drugs (DMARDs), according to the results of the POETYK PsA-1 study.
Deucravacitinib delivers superior efficacy, safety in active PsA
10 Jul 2025
MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis
Apremilast, an oral immunomodulating phosphodiesterase-4 inhibitor, reduces inflammation in individual joints and clinical dactylitis as per MRI in patients with psoriatic arthritis (PsA), according to the results of a dynamic contrast-enhanced MRI (DCE-MRI) analysis of the phase IV, open-label MOSAIC study.
